Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy

NCT07306624 is registered in ClinicalTrials.gov with STCube, Inc. as lead sponsor.

NCT NCT07306624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07306624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Lead sponsor
STCube, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2026
Completion date
August 31, 2027
Enrollment
62 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer